02-24-2022, 04:37 PM
From Marketwatch....
Moderna said Thursday it expects COVID-19 to become endemic in 2023, meaning it will be another seasonal disease that can be managed with vaccines and treatments
The biotech made the comment as it reported earnings, showing it chalked up nearly $7 billion in sales of its COVID-19 vaccine in the fourth quarter, boosting profit to a consensus-beating $4.8 billion, or $11.29 a share, after a loss in the year-earlier period.
Moderna said Thursday it expects COVID-19 to become endemic in 2023, meaning it will be another seasonal disease that can be managed with vaccines and treatments
The biotech made the comment as it reported earnings, showing it chalked up nearly $7 billion in sales of its COVID-19 vaccine in the fourth quarter, boosting profit to a consensus-beating $4.8 billion, or $11.29 a share, after a loss in the year-earlier period.